Publications by authors named "C Bruckert"
Article Synopsis
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors, like dapagliflozin, may reduce the risk of cardiovascular issues and possibly prevent blood vessel thickening after injury, which is not well understood.
- In a study with male rats, dapagliflozin reduced neointima thickening by 32% compared to control and also impacted vascular responses without altering certain inflammatory and oxidative gene expressions.
- The findings suggest that dapagliflozin works by affecting angiotensin and extracellular nucleotide signaling, indicating SGLT2 inhibitors could be a new approach for addressing vascular restenosis.
SGLT2 inhibitors (SGLT2i) showed pronounced beneficial effects in patients with heart failure but the underlying mechanisms remain unclear. We evaluated the effect of empagliflozin, selective SGLT2i, on hypertension-induced cardiac and vascular dysfunction. Male Wistar rats received diet with or without empagliflozin (30 mg/kg/day).
View Article and Find Full Text PDFCanada is among several countries to have implemented 'end-demand' criminalization frameworks for sex work. Drawing on interviews with sex workers (n = 200) in five cities, we employed multivariate logistic regression to identify associations with workplace violence. We also analysed descriptive data on trafficking and on workplace violence under end-demand legislation.
View Article and Find Full Text PDFBackground: Empagliflozin (empa), a selective sodium-glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective effect of empa was evaluated in an experimental model of metabolic syndrome, the obese ZSF1 rat, and its' lean control.
Methods: Lean and obese ZSF1 rats were either non-treated or treated with empa (30 mg/kg/day) for 6 weeks.